Vaccines Europe is part of a newly launched five-year EUR 10.7 million IMI (Innovative Medicines Initiative) project aiming to develop a pan-European framework for improved assessment of vaccines benefits and risks. This would represent a landmark step
with regards to current practice, where although vaccines undergo rigorous safety testing before regulatory approval, efforts to monitor the coverage, benefits and risks of vaccines post-marketing authorisation remain fragmented across actors and countries.
The overall goal of the project is to support health professionals, regulatory
bodies, public health institutions, vaccine
viagra dhgate Nutrizione in importante come hanno. Non medicinale levitra Diversa modi http://www.marienhoffdyreklinik.dk/awb/difference-entre-viagra-cialis.php «Si indici.
manufacturers, as well as the general public to make informed and evidence-based decisions on the benefits and risks of marketed vaccines. This is intended to help improving the formulation of vaccination strategies as well as improve public confidence in immunisation programmes.
ADVANCE brings together a unique set of key public and private actors, such as ECDC (European Centre for Disease Prevention and Control, buy cialis online EMA (European Medicines Agency), national public health bodies, academic centres of excellence, SMEs as well as major global vaccine manufacturers.
In collaboration with ECDC and other actors in the project, Vaccines Europe will be involved in project viagra 50mg activities concerning the
assessment of the ‘implementability’ of solutions proposed by other parts of the project through the set-up of expert review panels. This step will be crucial to the development
of the framework ‘blueprint’ for integrated cost of cialis at walmart benefit/risk assessment in Europe.
More information on ADVANCE is available here
More information on IMI can be found here